Final answer:
Rho-(D) immune globulin therapy should be administered to a client who is Rh-negative to prevent Hemolytic Disease of the Newborn (HDN). RhoGAM, a drug that temporarily prevents the development of Rh antibodies, is given to Rh-negative mothers to prevent a possible antigen-antibody reaction with an Rh-positive fetus.
Step-by-step explanation:
Rho-(D) immune globulin therapy should be administered to a client who is Rh-negative. Rh factor incompatibility can lead to Hemolytic Disease of the Newborn (HDN), which can be prevented by administering RhoGAM, a drug that temporarily prevents the development of Rh antibodies in the Rh mother. RhoGAM antibodies destroy any fetal Rh erythrocytes that may cross the placental barrier, reducing the risk of HDN.